Addus (ADUS) Q3 2025 Earnings Call Transcript

Addus HomeCare reported strong Q3 results, with revenue up 25% year over year to $362.3 million, adjusted EBITDA up 31.6% to $45.1 million, and adjusted EPS rising 20% to $1.56. Personal care and hospice were the main growth drivers, while Texas and Illinois rate increases should add about $17.7 million and $17.5 million of annualized revenue, respectively. The company also generated $51.3 million of operating cash flow, ended with $101.9 million of cash, and kept net leverage below 1x EBITDA, preserving flexibility for acquisitions.

Analysis

ADUS is quietly converting reimbursement wins into operating leverage faster than the market likely expects. The key second-order effect is not just incremental revenue from Texas/Illinois; it is that higher state funding should improve caregiver retention and hiring economics, which then feeds a self-reinforcing cycle of more billable hours, higher authorized-hour capture, and better census growth. That matters because the company’s organic growth is no longer purely price-driven — the mix is shifting toward volume, which is the cleaner path to durable margin expansion.

The hidden winner is hospice, not personal care. The home health-to-hospice bridge creates a structurally better referral funnel in overlapping markets, so even if home health remains pressured by CMS uncertainty, it can still function as an acquisition and referral asset rather than a standalone profit engine. That makes home health valuation less about current earnings and more about option value on cross-selling; the market may be over-discounting it because the segment-level P&L understates the contribution to hospice ADC and patient mix quality.

The main risk is timing, not thesis. If the final home health rule remains punitive and the clawback overhang persists, M&A in that bucket stays frozen for months, and ADUS could be forced to lean harder on lower-multiple personal care deals. Near term, Q4 should still be the earnings peak because of seasonality plus reimbursement flow-through, but the bigger catalyst is 2026 volume acceleration if wage pass-through actually tightens labor supply as management expects. The contrarian view is that ADUS may be underappreciated as a compounding platform rather than a reimbursement story: the leverage is in density, not just rates.

Key Decisions for Investors

• Go long ADUS into the final home health rule print, using a 1-3 month horizon; risk/reward favors upside if CMS softens the proposed cut or removes some clawback risk, with downside likely capped by strong PCS/hospice momentum.
• Add on pullbacks ahead of Q4 results; management is signaling peak-margin seasonality, so the setup is favorable for a near-term earnings beat and upward revisions to 2026 EBITDA expectations.
• Pair trade: long ADUS / short a home-health-heavy name with weaker reimbursement exposure over the next 3-6 months; ADUS has a better mix of personal care and hospice, plus more explicit cross-segment referral optionality.
• For a more tactical expression, buy ADUS call spreads expiring after the CMS final rule; the catalyst window is weeks, and the stock can re-rate quickly if regulatory uncertainty resolves favorably.
• If ADUS rallies hard on the next reimbursement headline, keep a trailing trim discipline: the primary risk is not fundamentals deteriorating, but the market already pricing in too much of the 2026 operating leverage before M&A and labor benefits fully land.